Vanda Pharmaceuticals heads into its third-quarter report with a story that has two very different halves. Its antipsychotic Fanapt is posting its best prescription numbers in more than a decade, and the pipeline calendar is crowded with late-2026 catalysts. Yet total revenue went backward last quarter, losses deepened and the stock has slid to the bottom of its recent range. The report due after the close on October 28 needs to show that the growth engine can finally outrun the drags.

Wall Street expects a loss of $0.72 per share on revenue of about $65.9 million. That revenue figure would mark 17% growth from the year-ago $56.3 million and a sharp jump from the $50.5 million reported in the second quarter. The projected loss would be narrower than last quarter's $1.04 but nearly double the $0.38 loss from a year earlier, a reminder that spending has been running well ahead of sales. Management reaffirmed its full-year revenue outlook of $240 million to $290 million, and the Street's $259.7 million estimate sits comfortably inside that range, though below the $265 million midpoint. The math is demanding. With roughly $102 million booked in the first half, Vanda needs about $138 million in the back half just to reach the low end, and consensus implies a fourth quarter north of $90 million.

Some of the expected sequential lift is mechanical. About $7 million of Hetlios shipments slipped from late June into early July, which should flatter third-quarter results. The more useful question is what Hetlios looks like underneath that timing shift. Sales fell to $5.6 million last quarter amid generic competition and specialty pharmacy destocking, and a figure that remains weak even after the catch-up would suggest the erosion is structural rather than temporary. Fanapt is the bigger swing factor. Second-quarter sales rose 23% from a year earlier to $36 million, with prescriptions up 31%, and the company is counting on Fanapt and the newly approved Bisanti to deliver $150 million to $170 million combined this year. One caution: wholesaler inventory of Fanapt ran slightly above its usual three-to-four week range, so a quarter of strong prescriptions paired with soft reported sales would point to destocking rather than faltering demand. Continued sequential improvement in Ponvori, which rose 27% last quarter to $7.9 million, would further support the case that the commercial rebuild is taking hold.

Nereus is the wild card. Wholesalers took $15.2 million of initial stock, but Vanda recognized only $1 million and held back $12.6 million because of uncertainty around patient demand and returns. Evidence of real pull-through, and with it the release of some of that constrained revenue, would go a long way toward validating the $10 million to $30 million product outlook. Early signs from the Bisanti launch would carry similar weight.

Costs matter just as much. Operating expenses climbed to $114.3 million last quarter, and cash fell to $170 million from $263.8 million at the start of the year. Management has promised that spending will begin to decline by year-end and fall more meaningfully in 2027. A third quarter showing expenses levelling off would make that promise more believable.

The market is skeptical. Shares have fallen 13.6% since the last report, trailing the S&P 500 by 14 points. At $4.01, they sit just above the post-earnings low of $3.97 and far below the 200-day average of $6.35. Sentiment has edged slightly more bearish than it was a quarter ago, though the shift is modest. With the stock pinned near its lows, the bar is less about beating estimates by a few cents and more about whether Vanda can show organic revenue momentum, excluding the Hetlios timing gain, that makes a back-end-loaded full-year outlook look achievable before the December catalysts arrive.